• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

News &
Media

  • Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

    4 September 2021
    Simply Wall St
    View More
  • From Backstreet to Highstreet: How Cannabis Has Entered the Mainstream

    18 August 2021
    The Market Herald

    Explore the $31.96 billion global cannabis market that is disrupting the healthcare and pharmaceutical industries.

    View More
  • Australia’s Neurotech Inks Cannabis Cultivation Partnership

    11 May 2021
    The Hemp Gazette

    Neurotech International Limited (ASX:NTI) has established a strategic medical cannabis cultivation partnership with CannaPacific Limited.

    View More
  • Neurotech just started world’s first THC-less cannabis study in autistic children

    6 May 2021
    Stockhead

    The Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.

    View More
  • Neurotech embarks on ground-breaking ASD trials

    5 May 2021
    Finfeed

    Neurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).

    View More
  • Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strains

    3 July 2020
    The Market Herald

    Neurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global.

    The proprietary cannabis strains will be medicinally used to treat neurological disorders such as autism, epilepsy and ADHD.

    View More
Previous
1 … 3 4 5

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1675266243anoit1675266243anret1675266243nihce1675266243torue1675266243n@ofn1675266243i1675266243

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus